(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 6.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Jazz Pharmaceuticals's revenue in 2024 is $3,843,375,000.On average, 10 Wall Street analysts forecast JAZZ's revenue for 2024 to be $255,525,039,760, with the lowest JAZZ revenue forecast at $252,253,031,427, and the highest JAZZ revenue forecast at $259,294,556,758. On average, 10 Wall Street analysts forecast JAZZ's revenue for 2025 to be $276,284,553,324, with the lowest JAZZ revenue forecast at $262,046,866,479, and the highest JAZZ revenue forecast at $293,404,663,661.
In 2026, JAZZ is forecast to generate $292,773,889,244 in revenue, with the lowest revenue forecast at $266,443,249,439 and the highest revenue forecast at $320,040,163,059.